Use of chemokine receptor CXCR5
US11542318B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 12, 2019 |
| Grant date | Jan 3, 2023 |
| Priority date | — |
| Expiry date | Sep 5, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2740/16043
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure provides use of chemokine receptor CXCR5, wherein CAR-T cells with enhanced chemotaxis are obtained by modifying chimeric antigen receptor T cells (CAR-T cells) utilizing the chemotactic signal between CXCR5 and its ligand CXCL13. The chemokine receptor CXCR5 can guide CAR-T cells to migrate to tumors. It has an excellent ability to enhance the chemotaxis of CAR-T cells, can specifically clear tumor cells, and effectively solve the problem of poor efficacy of the existing CAR-T therapy for solid tumors, thereby exhibiting broad application prospects and great market value.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.